Revance Therapeutics (NASDAQ:RVNC) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Revance Therapeutics (NASDAQ:RVNC) in a research note published on Monday. The firm issued a hold rating on the biopharmaceutical company’s stock.

Separately, Needham & Company LLC reaffirmed a “hold” rating on shares of Revance Therapeutics in a research note on Friday, January 17th. Nine investment analysts have rated the stock with a hold rating and one has given a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $8.39.

Revance Therapeutics Stock Performance

Revance Therapeutics stock opened at $3.65 on Monday. The firm has a market capitalization of $381.02 million, a P/E ratio of -1.89 and a beta of 0.90. The business has a 50-day moving average of $3.65 and a 200-day moving average of $3.78. Revance Therapeutics has a 1 year low of $2.30 and a 1 year high of $6.65.

Institutional Trading of Revance Therapeutics

A number of large investors have recently bought and sold shares of the business. Natixis bought a new position in Revance Therapeutics in the fourth quarter valued at approximately $31,000. Two Sigma Securities LLC acquired a new stake in shares of Revance Therapeutics during the fourth quarter worth $35,000. Alpine Global Management LLC bought a new stake in Revance Therapeutics in the 4th quarter valued at $37,000. RPO LLC acquired a new position in Revance Therapeutics in the 4th quarter worth $55,000. Finally, Fairfax Financial Holdings Ltd. Can bought a new position in Revance Therapeutics during the 4th quarter worth about $64,000. 97.70% of the stock is owned by institutional investors.

Revance Therapeutics Company Profile

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.